Low-dose IL-2 for Treg Expansion and Tolerance (LITE) (LITE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02949492

Recruitment Status : Terminated (Safety concerns)

First Posted : October 31, 2016

Last Update Posted : August 14, 2019

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

King's College Hospital NHS Trust

Information provided by (Responsible Party):

King's College London

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	January 31, 2019
Actual Study Completion Date :	January 31, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lim TY, Perpinan E, Londono MC, Miquel R, Ruiz P, Kurt AS, Kodela E, Cross AR, Berlin C, Hester J, Issa F, Douiri A, Volmer FH, Taubert R, Williams E, Demetris AJ, Lesniak A, Bensimon G, Lozano JJ, Martinez-Llordella M, Tree T, Sanchez-Fueyo A. Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans. J Hepatol. 2023 Jan;78(1):153-164. doi: 10.1016/j.jhep.2022.08.035. Epub 2022 Sep 7.

To Top